ArticleCancer science2019

Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.

Xinji Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.